Nanoviricides Inc (NNVC) 13F Positioning & Ownership Changes (Q2 2026)

NanoViricides, Inc. (NNVC) disclosed that it entered into a securities purchase agreement on July 24, 2026 with an investor for a registered direct offering. The offering includes roughly 2.42 million shares of common stock at $1.53 per share, plus pre-funded warrants for 100,000 shares and common warrants to buy up to 2,516,339 shares at $1.75 per share. The deal closed on July 27, 2026, bringing in about $3.8 million in gross proceeds before fees. The company also hired D. Boral Capital as placement agent (7% cash fee), and its CEO and principal stockholder TheraCour Pharma agreed to a 30-day lock-up. Proceeds are earmarked for working capital, capital expenditures, R&D, clinical trials, and possible acquisitions.

NanoViricides entered into an at-the-market sales agreement with D. Boral Capital LLC on July 17, 2026. The company can sell its common stock through the sales agent on a continuous basis, paying a 2.0% commission on gross proceeds. A prospectus supplement was filed under the existing shelf registration.